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OBJECTIVES The goal of this study was to determine whether the cardiostimulant effects of the endogenous
beta1-adrenergic receptor (AR) agonist, ()-norepinephrine are modified by polymorphic
(Serine49Glycine [Ser49Gly], Glycine389Arginine [Gly389Arg]) variants of beta1-ARs in
the nonfailing adult human heart.
BACKGROUND Human heart beta1-ARs perform a crucial role in mediating the cardiostimulant effects of
()-norepinephrine. An understanding of the significance of Ser49Gly and Gly389Arg
polymorphisms in the human heart is beginning to emerge, but not as yet in adult patients
who have coronary artery disease (CAD).
METHODS The potency and maximal effects of ()-norepinephrine at beta1-ARs (in the presence of
beta2-AR blockade with 50 nM ICI 118,551 [erythro-DL-1(7-methylindan-4-yloxy)-3-
isopropylamino-butan-2-ol]) for changes in contractile force and shortening of contractile
cycle duration were determined in human right atrium in vitro from 87 patients undergoing
coronary artery bypass grafting who were taking beta-blockers before surgery. A smaller
sample of patients (n  20) not taking beta-blockers was also investigated. Genotyping for
two beta1-AR polymorphisms (Ser49Gly and Gly389Arg) was determined from a sample of
blood taken at the time of surgery.
RESULTS ()-Norepinephrine caused concentration-dependent increases in contractile force and
reductions in time to reach peak force and time to reach 50% relaxation. There were no
differences in the potency or maximal effects of ()-norepinephrine in the right atrium from
patients with different Ser49Gly and Gly389Arg polymorphisms.
CONCLUSIONS The cardiostimulant effects of ()-norepinephrine at beta1-ARs were conserved across
Ser49Gly and Gly389Arg polymorphisms in the right atrium of nonfailing hearts from
patients with CAD managed with or without beta-blockers. (J Am Coll Cardiol 2002;40:
1275–82) © 2002 by the American College of Cardiology Foundation
The human beta1-adrenergic receptor (AR) performs a
crucial role in mediating the cardiostimulant effects of
()-norepinephrine in the human heart. Within the coding
block of the beta1-AR, 17 nucleotide substitutions have
been identified, resulting in seven amino-acid substitutions,
with two occurring in the extracellular amino-terminal and
the remainder in the intracellular carboxyl-terminal (1–5).
This raises several important questions concerning whether
beta1-AR polymorphisms contribute to the etiology of
disease and/or have a determining affect on patient progno-
sis. Intrinsically related to this is the question of whether
beta1-AR polymorphisms interact differently to ()-
norepinephrine, other beta1-AR stimulants, and beta1-
blockers. Results of studies addressing these questions are
emerging.
The search for associations between beta1-AR polymor-
phisms and disease have thus far extended to heart failure
(HF) and hypertension. An association between idiopathic
dilated cardiomyopathy in a small population (37 patients)
and the amino acid substitution of serine (Ser) (wild-type)
by glycine (Gly) (mutation) at amino acid position 49 in the
extracellular amino-terminal of the beta1-AR was observed
(5). In a study of a larger population of patients with
congestive HF (184 patients) with age-matched controls (77
patients), Bo¨rjesson et al. (4) showed no difference in
mutation (Ser49Gly) frequency, but they observed improved
survival in patients with the Gly49 mutation. Furthermore,
the difference was more pronounced in patients receiving
beta-blocker treatment.
The CARDIGENE population in France, comprising
426 patients with idiopathic dilated cardiomyopathy, was
investigated for an association with the substitution of
arginine (Arg) (mutant) for Gly (wild-type) at amino acid
position 389 in the cytoplasmic tail of the beta1-AR, but
none was observed (3). However, at a functional level, it was
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observed that patients with HF (left ventricular [LV]
ejection fraction 26  1%) homozygous for Gly389-
beta1-AR were associated with depressed exercise capacity
compared with their homozygous Arg389-beta1-AR coun-
terparts (6). An association between the homozygous
Arg389 genotype and increased diastolic blood pressure and
heart rate (HR) was observed in a population of hyperten-
sive patients (7). The authors speculated that hypertension
could be caused by increased activity of the Arg389 variant
and consequent elevated cardiac output (7). Both studies are
in line with original work at the molecular level, where it
was shown that clonal cell lines expressing only the Arg389
genotype had both greater basal and ()-isoproterenol-
stimulated adenylyl cyclase activity with tighter Gs-alpha-
protein coupling, than cells expressing only Gly389 (2).
These studies raise the fundamental question of whether
the potency and effectiveness of ()-norepinephrine at
human heart beta1-ARs is influenced by polymorphic
(Ser49Gly, Gly389Arg) variations. In young healthy adults,
this does not appear to be the case where exercise-mediated
increases in HR caused by cardiac stimulation of beta1-ARs
by neuronally released ()-norepinephrine were not differ-
ent for homozygous Gly389 and Arg389 groups (8,9), while
Ser49Gly polymorphisms have not been investigated yet. In
this study we investigated the cardiostimulant effects of
()-norepinephrine at both Ser49Gly and Gly389Arg poly-
morphisms directly on the human heart (in vitro) from
patients with coronary artery disease (CAD). We surveyed
531 patients who had undergone coronary artery bypass
graft (CABG) surgery at the Prince Charles Hospital and
ascertained that 78% were treated with a beta-blocker before
surgery. Perioperatively, some patients were also prescribed
infusions of dopamine and/or ()-norepinephrine to main-
tain cardiac output and perfusion pressure. We considered
that it was important to determine the significance of
beta1-AR polymorphism in this group of patients, both in
terms of the immediate effects of cardiostimulants and of
long-term administration of beta1-blockers.
This study showed a uniformity of agonist potencies and
effects of ()-norepinephrine at polymorphic (Ser49Gly
and Gly389Arg) beta1-ARs in the human right atrium from
patients treated with atenolol or metoprolol undergoing
CABG surgery. This observation is consistent with the
effects of endogenous ()-norepinephrine in healthy young
adults who were not treated with beta-blockers (8,9).
A preliminary account of this work was presented at the
40th National Scientific Conference of the Australian So-
ciety for Medical Research (10).
METHODS
This study was approved by The Prince Charles Hospital
ethics committee (EC9876).
Patients. Human right atrial appendages and arterial blood
samples were obtained from patients undergoing CABG
surgery at The Prince Charles Hospital who were taking
beta-blockers and who had given prior informed written
consent. A description of patient characteristics according to
genotype groupings is given in Table 1. Briefly, a compar-
ison between groups indicated that these were made up of
patients of similar age and body mass index, took similar
classes of medications including doses of beta-blocker
(atenolol/metoprolol), and had similar hemodynamic mea-
surements (LV ejection fraction, LV end-systolic and
-diastolic pressures). In addition, the patients making up
these groups had a similar distribution of risk factors
(hypercholesterolemia, hypertension, diabetes mellitus, obe-
sity, and history of smoking).
A smaller sample of patients (20 patients) who were not
taking beta-blockers before surgery were also investigated
for possible differences in the effects of ()-norepinephrine
that could be attributed to beta1-AR polymorphism. In
comparison with the overall cohort of beta-blocked patients,
non-beta-blocked patients were older (68  9 years [SD])
but had a similar LV ejection fraction (64  3%). One
reason for the exclusion of beta-blockers for the overall
management of these patients included the existence of
airways disease (eight patients). These patients received one
or all of inhalational beta-receptor agonists, corticosteroids,
and muscarinic receptor antagonists.
Preparation of tissues. After surgical removal, atrial tissues
were placed immediately into ice-cold pre-oxygenated mod-
ified Krebs solution (containing mM; Na 125, K 5,
Ca2 2.25, Mg2 0.5, Cl 98.5, SO4
2 0.5, HCO3
 32,
HPO4
2 1, ethylenediamine-tetraacetic acid 0.04) and
transported to the laboratory (within 5 min of surgical
removal), where atrial strips containing intact trabeculae
were dissected under continuous oxygenation. Tissues were
mounted onto electrode blocks in 50-ml tissue baths and
electrically stimulated to contract at 60 beats/min. Tissues were
incubated with 5 M phenoxybenzamine to block alpha-ARs
and neuronal and extraneuronal uptake of catecholamines and
50 nM ICI 118,551 to block beta2-ARs (11).
Catecholamine concentration-effect curves. Experiments
were carried out only in tissues with a basal contractile force
1 mN. Both current and past experience from this
laboratory have revealed that human right atrial tissues with
Abbreviations and Acronyms
AR  adrenergic receptor
Arg  arginine
bp  base pair
CABG  coronary artery bypass graft
CAD  coronary artery disease
DMSO  dimethyl sulphoxide
DNA  deoxyribonucleic acid
Gly  glycine
HF  heart failure
HR  heart rate
LV  left ventricular
PCR  polymerase chain reaction
Ser  serine
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basal contractile force 1 mN often exhibit poor developed
force and variable potencies to a variety of added stimulants.
In practice, few (approximately 1% to 2%) were excluded on
this basis.
Cumulative concentration-effect curves were established
to ()-norepinephrine in the presence of ICI 118,551
(erythro-DL-1[7-methylindan-4-yloxy]-3-isopropylamino-
butan-2-ol) (selective beta1-AR stimulation) by the se-
quential addition of agonist to the tissue bath followed by a
single concentration (200 M) of ()-isoproterenol to
obtain a maximal effect through stimulation of both beta1-
and beta2-ARs (11). Experiments were concluded by raising
the Ca2 concentration to 9.25 mM.
Recordings of contractile force and first derivative were
made on a Watanabe 12-channel recorder (Graphtec Corp.,
Yokohama, Japan). Time to reach peak force (determined as
the time in which the first derivative was positive) and time
to reach 50% relaxation were made from fast-speed (100
mm s1) recordings. Fast-speed recordings were obtained
from 77 of 87 patients.
Genotyping for Ser49Gly- and Gly389Arg- beta1-AR
polymorphisms. Genotyping for beta1-AR polymorphisms
was carried out after completion (including analysis) of
contractile studies and by different investigators, without
knowledge of the results of the contractile studies.
Genomic deoxyribonucleic acid (DNA) was isolated from
peripheral blood leukocytes using a standard salt extraction
method (12).
The identity of the amino acid at position 49 was
determined by customizing the reaction described previ-
ously by Maqbool et al. (1). The identity of the amino acid
at position 389 was determined by using the method
described by Mason et al. (2) with minor modifications. The
basic polymerase chain reaction (PCR) mixture was the
same for each loci, with the exception of the concentration
of dimethyl sulphoxide (DMSO) and the primer pair used.
For each PCR, 10 ng of DNA was added to the reaction
mixture with a final volume of 20 l containing 10%
RedTaq PCR reaction buffer, 0.2 mM of each deoxynucle-
otide triphosphate, 0.25 M of each primer, and 0.5 U
RedTaq Polymerase (RedTaq products from Sigma-Aldrich
Pty Ltd., Castle Hill, Australia). For position 49 genotyp-
ing, 5% DMSO was used, and the primers were 5-
CCGGGCTTCTGGGGTGTTCC-3 (sense) and 5-
GGCGAGGTGATGGCGAGGTAGC-3 (antisense).
Cycling conditions were 94°C for 3 min; 94°C for 30 s,
65°C for 30 s, 72°C for 45 s for 40 cycles, and 72°C for 7
min. Amplification produced a 564 base pair (bp) product. For
position 389 genotyping, 7.5% DMSO was used, and the
primers were 5-CCGCCTCTTCGTCTTCTTCAACTG-
Table 1. Summary of Patient Demographics, Drug History, and Hemodynamic Function
Ser49Ser Ser49Gly Gly49Gly Gly389Gly Gly389Arg Arg389Arg
Allelic frequency, n (%) 67 (77%) 18 (21%) 2 (2%) 6 (7%) 38 (44%) 43 (49%)
Male/female (% male) 60/7 (90%) 16/2 (89%) 2/0 (100%) 5/1 (83%) 35/3 (92%) 38/5 (88%)
Age (yrs)* 62  10 62  9 58 63  8 62  10 61  9
BMI (kg/m2) 27.4  0.5 29.9  1.0 29.8 26.7  1.6 28.1  0.6 28.0  0.7
Risk Factors†
Hypercholesterolemia 56 (84%) 17 (94%) 2 (100%) 5 (83%) 34 (89%) 36 (84%)
Hypertension 41 (61%) 10 (56%) 2 (100%) 5 (83%) 22 (58%) 26 (60%)
Obesity 14 (21%) 8 (44%) 1 (50%) 2 (33%) 10 (26%) 11 (26%)
Diabetes mellitus 16 (24%) 2 (11%) 2 (100%) 0 (0%) 8 (21%) 12 (28%)
Smoking 51 (76%) 13 (72%) 2 (100%) 5 (83%) 29 (76%) 32 (74%)
Medication
Beta-blocker
Atenolol, n (%) 47 (70%) 12 (67%) 1 (50%) 5 (83%) 27 (71%) 28 (65%)
Daily dose (mg) 46  3 59  5 50 45  15 47  4 52  4
Metoprolol, n (%) 20 (30%) 6 (33%) 1 (50%) 1 (17%) 11 (29%) 15 (35%)
Daily dose (mg) 100  12 100  22 50 100 100  17 93  14
ACE inhibitor, n (%) 26 (39%) 9 (50%) 1 (50%) 2 (33%) 17 (45%) 17 (40%)
AT2 antagonist, n (%) 2 (3%) 0 0 1 (17%) 0 1 (2%)
L-type Ca2 antagonist, n (%) 17 (25%) 6 (33%) 1 (50%) 1 (17%) 12 (32%) 11 (26%)
Nitrate, n (%) 48 (72%) 15 (83%) 1 (50%) 6 (100%) 27 (71%) 31 (72%)
Hypolipidemic, n (%) 47 (70%) 16 (89%) 2 (100%) 5 (83%) 26 (68%) 34 (79%)
Hypoglycemic, n (%) 9 (13%) 1 (6%) 1 (50%) 0 6 (16%) 5 (12%)
Hemodynamic
LVEF, % (n) 64  2 (46) 64  4 (12) 84 (1) 46  12 (3) 65  3 (27) 65  2 (29)
LVESP, mm Hg (n) 125  3 (48) 124  8 (12) 126 (1) 137  19 (4) 125  3 (27) 125  5 (30)
LVEDP, mm Hg 14.3  0.8 12.7  0.8 11.0 10.8  0.3 14.1  1.1 14.2  0.9
*Values for age are mean  SD. All other values are mean  SE. †Risk factors were defined as: hypercholesterolemia; fasting total cholestererol (5.5 mmol/l), triglycerides
(2.2 mmol/l), high-density lipoprotein (1.1 mmol/l), low-density lipoprotein (4.0 mmol/l), hypertension, systolic blood pressure 160 mm Hg and/or diastolic blood
pressure 95 mm Hg or evidence of anti-hypertensive medication, Obesity; BMI (30 kg/m2), diabetes mellitus: glucose (7.8 mmol/l), hemoglobin Alc (6%), or evidence
of hypoglycemic medication or diet control, Smoking: positive patient documented history. Data from the groups (Ser49Ser, Ser49Gly, Gly389Gly, Gly389Arg, Arg389Arg) were
not different from each other (p  0.05).
ACE  angiotensin-converting enzyme; Arg  arginine; BMI  body mass index; Gly  glycine; LVEF  left ventricular ejection fraction; LVEDP  left ventricular
end-diastolic pressure; LVESP  left ventricular end-systolic pressure; Ser  serine.
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3 (sense) and 5-TGGGCTTCGAGTTCACC-
TGCTATC-3 (antisense). Cycling conditions were 94°C for
3 min; 94°C for 30 s, 63°C touchdown to 58°C for 30 s, 72°C
for 45 s for 5 cycles; 94°C for 30 s, 58°C for 30 s, 72°C for 45 s
for 35 cycles, and 72°C for 7 min. The resulting product was
463 bp. Restriction digestion was used to distinguish between
the alleles at both positions. At position 49, the Gly49 allele
contained an Eco 0109 I restriction site resulting in products of
345 bp and 219 bp while the Ser49 allele remained uncleaved.
The restriction enzyme BsmF1 cleaved at position 389 if the
Gly389 allele was present, resulting in products of 352 and 111
bp but remained uncleaved if the Arg389 allele was present.
Digestion products were run on a 2% agarose gel containing
ethidium bromide and visualized using a Molecular Imager FX
(Bio-Rad Laboratories Pty Ltd., Hercules, California).
The results of restriction enzyme genotyping were veri-
fied by direct sequencing. A DNA template was prepared
for sequencing by PCR of the fragment purified by the
Promega Wizard kit. Sequencing was performed using the
Applied Biosystems PRISM system using an automated
sequencer (QIMR Sequencing Facility, Brisbane, Austra-
lia).
Statistics and calculations. Data are expressed as mean 
SE or SD where indicated. Comparisons between the
midpoints of cumulative concentration-effect curves
(logEC50 values) for ()-norepinephrine determined
from Ser49Ser and Ser49Gly groups were carried out using
the Student t test. Comparisons between logEC50 values
for ()-norepinephrine for Gly389Gly, Gly389Arg, and
Arg389Arg groups were carried out using a one-way anal-
ysis of variance. The Student t test (Ser49Ser, Ser49Gly)
and one-way analysis of variance statistical tests were used to
compare the maximal effects of ()-norepinephrine (relative
to ()-isoproterenol, I.A. (maximal effect of ()-
norepinephrine relative to ()-isoproternol); relative to
Ca2, %Ca2). Differences between experimental data were
assessed and tested for significance at the 95% confidence
interval (p  0.05). Data presented as “numbers of patients”
were analyzed with either chi-square test or Fisher exact test
for differences between groups. Homozygous Gly49 pa-
tients were excluded from all statistical analyses due to low
patient number (two patients).
RESULTS
Patient population and genotyping. Eighty-seven pa-
tients taking beta-blockers were recruited (Table 1) and
genotyped for Ser49Gly- and Gly389Arg-beta1-AR poly-
morphisms (Fig. 1). Allele frequencies of 0.87 and 0.13 for
Ser49 and Gly49, respectively, and 0.29 and 0.71 for
Gly389 and Arg389, respectively, were observed (Table 1).
Positive inotropic and lusitropic effects of ()-
norepinephrine at Ser49Gly- and Gly389Arg -beta1-AR
polymorphisms in right atrium from patients taking
beta1-blockers before surgery. Right atrial trabeculae were
characterized by strong basal contractile forces that did not
differ among the beta1-AR polymorphic groups (Fig. 2, p
0.05). Stimulation of beta1-ARs with ()-norepinephrine
caused concentration-dependent increases in contractile
force and shortening of the time to reach peak force and
time to reach 50% relaxation (Fig. 2, Table 2). There were
no differences in potency or maximal effects of ()-
norepinephrine at Ser49Gly or Gly389Arg polymorphisms
(p  0.05). Further analysis also revealed no differences
when Ser49Gly polymorphisms were considered in patients
homozygous for Arg389 or Gly389Arg polymorphisms
were considered in patients homozygous for Ser49 (p 
0.05, data not shown).
Figure 1. Genotyping of the beta1-adrenergic receptor at nucleotide 145 (Ser49Gly) (A) and 1165 (Gly389Arg) (B) in patients undergoing coronary artery
bypass grafting from which the right atrium was obtained and used to assess the contractile effects of ()-norepinephrine at polymorphic beta1-adrenergic
receptors. The figure shows polymerase chain reaction fragments of the predicted length after endonuclease digestion to discriminate between patients
homozygous for Ser49, Gly49, or heterozygous for Ser49Gly (A) or homozygous for Gly389, Arg389, or heterozygous for Gly389Arg (B). Arg  arginine;
bp  base pair; Gly  glycine; Ser  serine.
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Figure 2. Concentration-dependent effects of ()-norepinephrine for changes in contractile force, time to reach peak force, and time to reach 50%
relaxation (t50) through activation of Ser49Gly- and Gly389Arg-polymorphisms of the beta1-adrenergic receptor in human right atrium. Contractile force
is expressed in terms of absolute force (mN). Experiments were completed by incubation of tissues with 200 M ()-isoproterenol to maximally stimulate
both beta1- and beta2-adrenergic receptors followed by raising the concentration of Ca
2 to 9.25 mM. Values shown are mean SEM, where SEM values
were determined from each specific log ()-norepinephrine concentration. Errors not shown when smaller than symbol. Values in parenthesis show
(tissue number/patient number). Arg  arginine; Gly  glycine; Ser  serine.
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Does long-term administration of beta1 blockers nullify
possible differences between beta1-AR polymorphisms? To
determine whether long-term administration of beta1-AR
blockers nullifies differential ()-norepinephrine effects at
beta1-AR polymorphisms, we investigated the effects of
()-norepinephrine in the right atrium of patients who did
not receive beta-blockers before surgery. In a small group of
patients (n  20), a small (2.4-fold) reduction in the po-
tency of ()-norepinephrine for positive inotropic effects
was observed compared with patients receiving beta1-
blockers before surgery. However, there were no differences
in the potency or maximal effects of ()-norepinephrine
between homozygous Ser49 patients and those carrying the
Gly49 variant, and there were also no differences in potency
between homozygous Arg389 patients and those carrying
the Gly389 variant (p  0.05, Table 3).
DISCUSSION
()-Norepinephrine has similar potencies and efficacies at
two beta1-AR polymorphisms, Ser49Gly and Gly389Arg
for changes in contractile force and shortening of contractile
cycle in the right atrium of non-failing hearts from patients
with CAD undergoing CABG surgery.
Beta1-AR polymorphisms and function in the human
heart. Our study was motivated by the need to determine
the clinical significance of beta1-AR polymorphisms directly
in the human heart. In this study we used a carefully defined
population comprised of patients undergoing CABG sur-
gery. In this group of patients, therapeutic strategies
often utilize the beta1-AR. Beta1-blockers are commonly
used to manage patients with CAD, and if they proceed
to CABG surgery, there is the possibility they may also
receive inotropic support with dopamine and/or ()-
norepinephrine perioperatively. For this group of patients, two
beta1-AR polymorphisms, Ser49Gly and Gly389Arg, did
not differentially affect ()-norepinephrine effects at the
beta1-AR.
The same conclusion for Gly389Arg was also reached in
two recent in vivo studies of exercise-induced (endogenous
()-norepinephrine), cardiac effects in young healthy indi-
viduals (8,9). The human right atrial appendage from which
we obtained right atrial muscle could also be considered to
Table 2. Inotropic and Lusitropic Potencies and Intrinsic Activities of ()-Norepinephrine at
Polymorphic Beta1-Adrenergic Receptors in Right Atrial Trabeculae From Patients Having
Long-Term Treatment With Beta-Blockers
Effect Genotype LogEC50 IA %Ca
2 n
Force Ser49Ser 7.4  0.1 0.99  0.01 79.9  2.3 102/67
Ser49Gly 7.4  0.1 1.01  0.02 83.3  2.9 28/18
Gly49Gly 7.5 1.02 69.2 2/2
tpf Ser49Ser 7.5  0.1 1.04  0.04 83/58
Ser49Gly 7.5  0.1 0.99  0.05 19/14
t50 Ser49Ser 7.2  0.1 1.08  0.04 69/51
Ser49Gly 7.0  0.1 1.03  0.06 18/13
Force Gly389Gly 7.4  0.1 0.98  0.03 86.0  3.7 9/6
Gly389Arg 7.4  0.1 1.01  0.01 80.2  2.4 58/38
Arg389Arg 7.4  0.1 0.99  0.02 80.4  3.4 65/43
tpf Gly389Gly 7.9  0.3 0.95  0.05 7/5
Gly389Arg 7.5  0.1 0.99  0.03 45/33
Arg389Arg 7.6  0.1 1.08  0.05 51/35
t50 Gly389Gly 7.5  0.4 0.94  0.13 6/5
Gly389Arg 7.3  0.1 1.01  0.04 44/32
Arg389Arg 7.1  0.1 1.10  0.06 37/27
Intrinsic activity (IA) was calculated as the fraction of the maximum effect of ()-norepinephrine compared with the response
of ()-isoproterenol (200 M) causing maximal effects through beta1 beta2-adrenergic receptors. %Ca
2 was calculated by
comparing the maximal effect of ()-norepinephrine with the response obtained by raising Ca2 to 9.25 mM. n values show
tissues/patients from which data were obtained.
Arg  arginine; Gly  glycine; Ser  serine; tpf  time to reach peak force; t50  time to reach 50% relaxation.
Table 3. Inotropic Potencies and Intrinsic Activities of ()-Norepinephrine at Polymorphic
Beta1-Adrenergic Receptors in Right Atrial Trabeculae From Patients Not Having Long-Term
Treatment With Beta-Blockers
Effect Genotype LogEC50 IA %Ca
2 n
Force Ser49Ser 7.1  0.1 1.00  0.01 83.7  3.1 21/14
Ser49Gly 7.0  0.1 0.99  0.02 87.8  2.8 9/6
Force Gly389Arg 7.1  0.1 1.01  0.02 84.9  4.6 9/5
Arg389Arg 7.0  0.1 0.99  0.01 85.4  2.9 21/15
Intrinsic activity (IA) was calculated as the fraction of the maximum effect of ()-norepinephrine compared with the response
of ()isoproterenol (200 M) causing maximal effects through beta1-  beta2-adrenergic receptors. %Ca
2 was calculated by
comparing the maximal effect of ()-norepinephrine with the response obtained by raising Ca2 to 9.25 mM. n values show
tissues/patients from which data were obtained.
Abbreviations as in Tables 1 and 2.
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be “normal” for the age group represented by CABG
surgery patients. However, the conclusions reached in these
studies for the effects of ()-norepinephrine at Gly389Arg-
beta1-ARs differ from those obtained by Sandilands et al.
(13). In the human right atrium from non-failing patients,
they observed a 3.6-fold increase in potency of ()-
norepinephrine at Arg389- compared with Gly389-beta1-
ARs. However, before direct comparisons can be made with
our study, experimental differences need to be considered,
most notably the weaker basal contractile force of right atrial
muscle (0.79 to 0.81 mN) than in our study (8.0 to 9.4 mN),
which most probably resulted in the observed three- to
eleven-fold lower ()-norepinephrine potency and consid-
erably smaller developed force (1.4 to 2.2 mN) than in our
study (5.3 to 7.2 mN).
The observation of enhanced ()-norepinephrine effect
at human heart Arg389-beta1-ARs observed by Sandilands
et al. (13) is consistent with molecular studies at CHW-
1102 fibroblast cells and COS-7 cells transfected with
Gly389- or Arg389-beta1-ARs. In these cell lines, basal and
maximal isoproterenol-stimulated adenylyl cyclase activities
were greater for Arg389-beta1-ARs, associated with “tight-
er,” more efficient coupling between receptor and Gs-alpha-
protein (2). Collectively, these data also correctly predict
differential phenotypes in patients with HF, where the
presence of Gly389-beta1-ARs is associated with reduced
exercise capacity. The possibility of differential Gly389- and
Arg389-beta1-AR–mediated cardiostimulant effects could
also be investigated directly in human ventricles from
explanted hearts.
Does long-term administration of beta-blockers nullify
beta1-AR polymorphic differences? We observed a uni-
formity of ()-norepinephrine cardiostimulant effects at
Ser49- and Ser49Gly-beta1-ARs and also at Arg389- and
Arg389Gly-receptors in right atrial tissues of non-failing
hearts from patients not receiving beta1-blockers before
surgery. This conclusion is also consistent with in vivo
studies of exercise (endogenous ()-norepinephrine) in-
duced changes in HR, which were determined in young
healthy volunteers not taking beta-blockers (8,9).
The antihypertensive effects (reduced systolic/diastolic
blood pressure, reduced HR) of long-term administration of
two beta1-AR blockers (50 mg atenolol and 5 mg bisopro-
lol) were indistinguishable at Gly389Arg-beta1-AR poly-
morphisms (14). Thus, taken together, it is unlikely that the
long-term administration of the beta1-blockers atenolol or
metoprolol by patients in this study has caused differential
effects at beta1-AR polymorphisms.
Overall, we observed a small (2.4-fold) increase in po-
tency for ()-norepinephrine-mediated increases in con-
tractile force in human right atrium from patients receiving
atenolol or metoprolol compared with patients not receiving
beta-blockers before surgery. In this respect there was no
difference between atenolol or metoprolol (overall:
logEC50 for ()-norepinephrine-mediated increase in
contractile force without consideration for polymorphic
beta1-ARs; atenolol: 7.42  0.045, n  95 tissues; meto-
prolol: 7.42  0.05, n  37 tissues, p  1). This probably
reflects an overall increase in stimulatory Gs-alpha-protein-
coupled receptor function in human right atrium, previously
observed for beta2-ARs, H2-receptors, 5-HT4 receptors,
and for RO363 at beta1-ARs (11,15,16), which is uniform
across all beta1-AR polymorphisms.
Study limitations. Our investigation focused on two
beta1-AR polymorphisms, Ser49Gly and Gly389Arg, while
there is evidence for five other polymorphisms (5). It could
be argued that a complete phenotypic description of
beta1-AR function requires simultaneous consideration of
all polymorphisms. Nevertheless, the uniformity and con-
sistency of effects of ()-norepinephrine across two poly-
morphisms in our study population were striking. This may
not be the case as argued above for other pathologies where
beta1-AR function is attenuated. Our study did not find a
mechanistic explanation for the increased survival benefit
observed in congestive HF patients having Gly49-beta1-
ARs compared with patients homozygous for Ser49. There-
fore, it may be necessary to investigate molecular mecha-
nisms of Ser49Gly polymorphisms directly in failing human
heart preparations (17), or in clonal cell lines (2).
Conclusions. Despite the presence of beta1-AR polymor-
phisms in the human population, this study showed con-
servation of the effects of ()-norepinephrine at two poly-
morphisms in the right atrium of adult non-failing hearts.
Differences between polymorphic beta1-ARs may be more
apparent in pathologic conditions such as HF.
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